Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$516.66 USD

516.66
270,817

+9.24 (1.82%)

Updated Nov 5, 2024 10:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

Varian's ProBeam Compact System Picked by University of Miami

Varian (VAR) sees notable developments in its Proton Solutions business of late.

DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?

DexCom (DXCM) has various favorable factors to maintain the current high.

Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates

Veeva Systems (VEEV) issues a strong guidance for fiscal 2020.

Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y

Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.

What's in Store for Cooper Companies (COO) in Q3 Earnings?

Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.

Veeva (VEEV) Introduces MuleSoft Connector for Vault Platform

Veeva's (VEEV) Vault platform sees a slew of developments in recent times.

Allscripts' (MDRX) Veradigm Collaborates With Komodo Health

Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.

Here's Why You Should Add Stryker (SYK) to Your Portfolio

Stryker (SYK) gains from core segments in the second quarter of 2019.

Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance

Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.

Here's Why You Should Snap Up Baxter International (BAX) Now

For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.

Accuray (ARAY) Reports Loss in Q4, Revenues Beat Estimates

Accuray (ARAY) expects fiscal 2020 revenues to be impacted by China tariffs.

Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised

Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.

Nevro (NVRO) Q2 Loss Wider Than Expected, Revenues Down Y/Y

Nevro (NVRO) sees dismal segmental performance in Q2.

Inogen (INGN) Q2 Earnings Miss Estimates, 2019 View Lowered

Inogen (INGN) gains from international revenues in Q2; slashes 2019 guidance.

Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues

Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.

Allscripts (MDRX) Q2 Earnings Top Estimates, Revenues Lag

Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.

Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark

Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.

Benjamin Rains headshot

Adidas Slips, Lyft Climbs, Uber Earnings & Why Intuitive Surgical Stock is a Strong Buy | Free Lunch

On today's episode of Free Lunch here at Zacks, Associate Stock Strategist Ben Rains offers a quick global economic update. The episode also dives into Adidas (ADDYY), Lyft (LYFT), and Uber (UBER) earnings, and more...

Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates

Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.

LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss

LHC Group (LHCG) second-quarter results benefit from home health and hospice admissions and higher revenues.

OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates

OPKO Health (OPK) gains from RAYALDEE prescriptions in Q2.

Wright Medical (WMGI) Earnings Beat in Q2, Guidance Slashed

Wright Medical (WMGI) gains from Upper and Lower Extremities units in Q2; slashes 2019 view.

Cardiovascular Systems (CSII) Earnings Match Estimates in Q4

We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

CVS Health (CVS) Beats on Q2 Earnings, Raises '19 Guidance

CVS Health's (CVS) second-quarter top-line growth in Pharmacy Services segment is backed by an uptick in specialty services.

Avanos (AVNS) Q2 Earnings Beat Estimates, Revenues Miss

Avanos (AVNS) second-quarter results benefit from higher revenues, strong segmental performance and expansion in margins.